RE:RE:RE:RE:Assistance from one of the best firms.... With the Health Service Medical Supplies (Costs) Bill to be brought into law possibly by the end of this month or early next month and the involvement of Concordia in the following CMA investigations one would have to think that it will obviously take time to understand which drugs may be involved in any price reductions before a budget for the year can be created.
I still think that Concordia will not be the biggest loser in the CMA cases currently under investigation.
In both the Hydrocortisone and suspected unfair pricing cases Actavis UK will pay the most with Cinven next followed by Allergan and Concordia.
JMO
Contains Parliamentary information licensed under the Open Parliament Licence v3.0.
Hydrocortisone Tablets Objections
April to May 2017 Receipt of written and oral representations on the statement of objections.
March 2017 Statement of objections issued.
Suspected unfair pricing
April 2017 Decision whether or not to proceed with the investigation or to close the investigation.
October 2016 to April 2017 Initial investigation, information gathering, including issuance of formal or information requests and parties’ responses. CMA analysis and review of parties’ responses to information requests. Potential state of play meetings with parties under investigation.